These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 20128706

  • 1. Tyrosine kinase inhibitors to treat liver cancer.
    Huynh H.
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):13-26. PubMed ID: 20128706
    [Abstract] [Full Text] [Related]

  • 2. Targeted therapy of hepatocellular cancer.
    Wysocki PJ.
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [Abstract] [Full Text] [Related]

  • 3. Molecularly targeted therapy in hepatocellular carcinoma.
    Huynh H.
    Biochem Pharmacol; 2010 Sep 01; 80(5):550-60. PubMed ID: 20371362
    [Abstract] [Full Text] [Related]

  • 4. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA, Galle PR.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):615-29. PubMed ID: 20374038
    [Abstract] [Full Text] [Related]

  • 5. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May 01; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

  • 6. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M, Ueshima K.
    Oncology; 2010 Jul 01; 78 Suppl 1():154-66. PubMed ID: 20616599
    [Abstract] [Full Text] [Related]

  • 7. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M, González Moreno L, Trapero-Marugán M, Medina J, Moreno-Otero R.
    Aliment Pharmacol Ther; 2008 Dec 01; 28(11-12):1269-77. PubMed ID: 18808443
    [Abstract] [Full Text] [Related]

  • 8. Systemic therapies in hepatocellular carcinoma.
    Wörns MA, Weinmann A, Schuchmann M, Galle PR.
    Dig Dis; 2009 Dec 01; 27(2):175-88. PubMed ID: 19546557
    [Abstract] [Full Text] [Related]

  • 9. Targeted therapies for hepatocellular carcinoma.
    Skelton MR, O'Neil B.
    Clin Adv Hematol Oncol; 2008 Mar 01; 6(3):209-18. PubMed ID: 18391920
    [Abstract] [Full Text] [Related]

  • 10. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
    Finn RS.
    Clin Cancer Res; 2010 Jan 15; 16(2):390-7. PubMed ID: 20068087
    [Abstract] [Full Text] [Related]

  • 11. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L, Santoro A.
    Dig Liver Dis; 2010 Jul 15; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [Abstract] [Full Text] [Related]

  • 12. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS.
    Semin Liver Dis; 2013 Feb 15; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [Abstract] [Full Text] [Related]

  • 13. Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
    Huynh H, Ong RW, Li PY, Lee SS, Yang S, Chong LW, Luu DA, Jong CT, Lam IW.
    Anticancer Agents Med Chem; 2011 Jul 15; 11(6):560-75. PubMed ID: 21554207
    [Abstract] [Full Text] [Related]

  • 14. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW, Poon RT.
    Oncology; 2007 Jul 15; 72 Suppl 1():30-44. PubMed ID: 18087180
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Jul 15; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 16. Systemic therapy for hepatocellular carcinoma.
    Thomas MB.
    Cancer J; 2008 Jul 15; 14(2):123-7. PubMed ID: 18391618
    [Abstract] [Full Text] [Related]

  • 17. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
    Frau M, Biasi F, Feo F, Pascale RM.
    Mol Aspects Med; 2010 Apr 15; 31(2):179-93. PubMed ID: 20176048
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.
    Anticancer Drugs; 2010 Mar 15; 21(3):326-32. PubMed ID: 20016366
    [Abstract] [Full Text] [Related]

  • 19. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J.
    Expert Opin Investig Drugs; 2010 May 15; 19(5):605-14. PubMed ID: 20367532
    [Abstract] [Full Text] [Related]

  • 20. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
    Zender L, Kubicka S.
    Onkologie; 2008 Oct 15; 31(10):550-5. PubMed ID: 18854656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.